Company profile
BioRestorative Therapies, Inc.
NASDAQ: BRTX · Healthcare · Biotechnology
#954 of 1,418 Healthcare companies by revenue32nd-percentile growth
EA Score
38DFH 16DQ 63GM 51SS 45
v0.1 · 65/100 weight · provisional
↑ disclosure history, 3-yr revenue growth · ↓ return on equity, return on assets
Methodology →Revenue TTM
$357.9k
Rev growth YoY (TTM)
-8.5%
Net income (FY)
-$14.2M
Employees
14
as of 2026-08-24
Market cap
$5.5M
as of 2026-08-24
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$359.7k$359.7k2025
Net income-$14.2M-$14.2M2025
Operating income-$15.6M-$15.6M2025
Total assets$4.1M$4.1M2025
Liabilities$3.7M$3.7M2024
Equity$356.7k$356.7k2025
Revenue trend
FY2018 – FY2025 · USD
FY18
FY19
FY20
FY21
FY22
FY23
FY24
FY25
Revenue by segment
Filed disclosures · FY2025
By product
Product83%
Royalty17%
By geography
Not disclosed.
The read
What is BioRestorative Therapies, Inc.’s revenue?
BioRestorative Therapies, Inc. booked $359.7k in FY2025 revenue, contracting 10% year over year — slower than 68% of Healthcare companies we track, at a -3959.4% net margin.
Peers · Healthcare
Lyra Therapeutics, Inc.30DOMID Holdings, Inc.48DAmerica Great Health39DHealth Sciences Group, Inc.——Ultimate Sports, Inc.——Core One Labs Inc.——Neighbors
Suffolk →Key facts
CEOKatharyn Field
SectorHealthcare
IndustryBiotechnology
HeadquartersMelville, NY
ExchangeNASDAQ: BRTX
Employees14
IPO date2012-12-05
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.